Back to top

Image: Bigstock

Integra LifeSciences' Organic Growth Strong on New Products

Read MoreHide Full Article

On Sep 2, we issued an updated research report on Integra LifeSciences Holdings Corporation (IART - Free Report) . The company has been noticing certain major developments overseas. However, a tough competitive landscape is a concern.

This New Jersey-based company is a leading developer, manufacturer and marketer of surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics and general surgery.

Shares of this Zacks Rank #2 (Buy) company have outperformed its industry in the past three months. The stock has rallied 29.2% compared with the industry’s 8% rise.

Integra LifeSciences exited the second quarter of 2019 on a solid note. We are upbeat about year-over-year revenue growth across both its key business segments. Several product launches including CereLink ICP monitor and CertasPlus family of Hydrocephalus management products in the quarter buoy optimism on the stock. In the same period, the company successfully completed its first clinical case using DuraGen in Japan. Expansion of gross and operating margins and a raised EPS guidance for 2019 are encouraging.

Benefiting from product launches and an enhanced sales force performance, the company expects faster organic growth during the second half of 2019. In the second quarter, within Codman Specialty Surgical segment, the company began the commercial launch of its products ahead of schedule.

Integra LifeSciences is looking forward to investment opportunities in the Asian market for growing its business much faster than in the United States and also certain parts of its international operations. In line with this strategy, the company is preparing to launch several products in China and Japan. Turning to Europe, management feels encouraged about the growth potential of this region with Tissue Technologies business and CUSA Clarity product scheduled to be launched on the continent.

Meanwhile, the company faces severe competition in the surgical implants and the medical instruments market. It needs consistent innovation to ward off rivalry. Moreover, consolidations in the industry could cause an acute pricing pressure.

Other Key Picks

A few other top-ranked stocks in the broader medical space are Medtronic (MDT - Free Report) , Baxter (BAX - Free Report) and NuVasive (NUVA - Free Report) , each carrying the same favorable Zacks Rank as Integra LifeSciences.

Medtronic’s long-term earnings growth rate is expected at 7.13%.

Baxter’s long-term earnings growth rate is projected at 12.8%.

NuVasive’s long-term earnings growth rate is estimated to be 12.75%.

Legalizing THIS Could Be Even Bigger than Marijuana

Americans spend an estimated $150 billion in this industry every year… more than twice as much as they spend on marijuana. Now that 8 states have fully-legalized it (with several more states following close behind), Zacks has identified 5 stocks that could soar in response to the powerful demand. One industry insider described the future as “mind-blowing” – and early investors can still get in ahead of the surge.

See these 5 “sin stocks” now >>